Michael Barbella, Managing Editor07.13.22
CartiHeal is officially now part of Bioventus Inc.
The company has completed its $450 million acquisition, first announced in early April. The deal came to light shortly after the March 29 U.S. Food and Drug Administration (FDA) premarket approval (PMA) of CartiHeal's Agili-CTM implant. Agili-C was granted Breakthrough Device Designation by the FDA in 2020 and is indicated for the treatment of International Cartilage Repair Society grade III or above knee–joint surface lesions, with a total treatable area of 1-7 cm2 for patients without severe osteoarthritis (Kellgren-Lawrence grade 0-3).
“We are excited to add CartiHeal to our diverse portfolio of active healing solutions,” said Ken Reali, Bioventus’ CEO. “CartiHeal represents an important breakthrough for the treatment of osteoarthritis and osteochondral defects of the knee with significant medium- and long-term potential as evidenced by the robust data generated from its pivotal clinical trial showing superiority to current treatments. We believe that the addition of CartiHeal will complement our joint preservation technologies and specifically our HA business, further supporting our short- and mid-term growth drivers and helping us to deliver on our goal of sustained double-digit revenue growth. We welcome the CartiHeal team to Bioventus and look forward to bringing this life-improving technology to as many patients as possible.”
CartiHeal is an attractive alternative for the approximately 650,000 U.S. patients that receive microfracture or debridement annually and can potentially delay the need for a total knee replacement in patients with joint surface lesions of the knee. The acquisition of CartiHeal is directly aligned with Bioventus’ sports medicine and total joint reconstruction call point and extends the Company's leadership position in joint preservation technologies. In a randomized controlled clinical trial, CartiHeal’s Agili-C implant demonstrated superiority to either microfracture or debridement.
Bioventus delivers products that help people heal quickly and safely. The Innovations for Active Healing from Bioventus include offerings for pain treatment, restorative therapies, and surgical solutions.
The company has completed its $450 million acquisition, first announced in early April. The deal came to light shortly after the March 29 U.S. Food and Drug Administration (FDA) premarket approval (PMA) of CartiHeal's Agili-CTM implant. Agili-C was granted Breakthrough Device Designation by the FDA in 2020 and is indicated for the treatment of International Cartilage Repair Society grade III or above knee–joint surface lesions, with a total treatable area of 1-7 cm2 for patients without severe osteoarthritis (Kellgren-Lawrence grade 0-3).
“We are excited to add CartiHeal to our diverse portfolio of active healing solutions,” said Ken Reali, Bioventus’ CEO. “CartiHeal represents an important breakthrough for the treatment of osteoarthritis and osteochondral defects of the knee with significant medium- and long-term potential as evidenced by the robust data generated from its pivotal clinical trial showing superiority to current treatments. We believe that the addition of CartiHeal will complement our joint preservation technologies and specifically our HA business, further supporting our short- and mid-term growth drivers and helping us to deliver on our goal of sustained double-digit revenue growth. We welcome the CartiHeal team to Bioventus and look forward to bringing this life-improving technology to as many patients as possible.”
CartiHeal is an attractive alternative for the approximately 650,000 U.S. patients that receive microfracture or debridement annually and can potentially delay the need for a total knee replacement in patients with joint surface lesions of the knee. The acquisition of CartiHeal is directly aligned with Bioventus’ sports medicine and total joint reconstruction call point and extends the Company's leadership position in joint preservation technologies. In a randomized controlled clinical trial, CartiHeal’s Agili-C implant demonstrated superiority to either microfracture or debridement.
Bioventus delivers products that help people heal quickly and safely. The Innovations for Active Healing from Bioventus include offerings for pain treatment, restorative therapies, and surgical solutions.